Schertenleib stands out as exclusively dedicated to patent litigation with noteworthy strength in the life sciences and pharmaceuticals industries. The practice excels in high-stakes disputes, regulatory counsel and multi-jurisdictional matters and is headed by founder Denis Schertenleib, a physicist with a PhD in molecular neurobiology focusing on patent litigation, arbitration and pharma regulatory matters. Ombeline Degèze-Péchade is renowned for innovative patent and regulatory strategies, and Marc Lauzeral is a name to note for cross-border patent and SPC disputes.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Testimonials
Collated independently by Legal 500 research team.
- ‘A multidisciplinary team providing precise and efficient service tailored to each situation. No topics are off-limits in discussions; they take all of their clients' concerns into account.’
- ‘The Schertenleib team comprises highly skilled lawyers known for their sharp analytical minds and extensive patent litigiation experience, in particular in the pharmaceutical and life sciences sectors. Their profound understanding of the technical and scientific background enables them to deliver comprehensive legal analysis and advice that meticulously considers all relevant aspects. They are diligent, deeply committed, exceptionally knowledgeable, and consistently responsive.’
- ‘I truly appreciate collaborating with Ombeline Degrèze-Péchade and her team. She is remarkably responsive and accessible, offering outstanding legal advice thanks to her deep legal and scientific expertise and the many years of experience. Above all, working with her is always a genuine pleasure. Ombeline and the Schertenleib team are undoubtedly the top choice for all matters related to patent litigation, in particular in a pharmaceuticals context.’
- ‘The firm is highly specialist and has detailed technical experience. It is focussed on delivering the best possible outcomes for clients.’
- ‘Denis Schertenleib is a statesman of patent litigation. He drafts fully articulated and detailed arguments that leave no stone unturned.'
Key clients
- Recor Medical Inc. & Otsuka Medical Device
- Viatris
- Neuraxpharm
- Akwell Vigo Spain
- Sandoz
- Zentiva
- C-KORE
- Filorga
- Fill-Med
- TCL
- Bio-Rad
Work highlights
Represented Sandoz successfully in invalidity proceedings against Bayer’s patent relating to Rivaroxaban (marketed as Xarelto), one of Bayer’s blockbuster drugs and a strategic product for the client’s European portfolio.
Represented Viatris successfully in litigation initiated by Biogen before the Paris Court of First Instance, concerning dimethyl fumarate (DMF)—one of Biogen’s blockbuster drugs used in the treatment of multiple sclerosis.
Represented ReCor Medical Inc. and Otsuka Medical Devices Europe GmbH successfully in invalidity proceedings against Medtronic’s patent relating to an ultrasound renal neuromodulation device.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Denis Schertenleib
Other key lawyers
Ombeline Degèze-Péchade; Marc Lauzeral